InMed Pharmaceuticals Inc. – TSX:IN.TO
InMed Pharmaceuticals stock price today
InMed Pharmaceuticals stock price monthly change
InMed Pharmaceuticals stock price quarterly change
InMed Pharmaceuticals stock price yearly change
InMed Pharmaceuticals key metrics
Market Cap | N/A |
Enterprise value | 20.54M |
P/E | -2.76 |
EV/Sales | 35.75 |
EV/EBITDA | -1.51 |
Price/Sales | 44.41 |
Price/Book | 2.34 |
PEG ratio | 0.15 |
EPS | -2.3 |
Revenue | N/A |
EBITDA | -13.57M |
Income | -14.01M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -2434.21% |
Oper. margin | -2444.97% |
Gross margin | 51.13% |
EBIT margin | -2444.97% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInMed Pharmaceuticals stock price history
InMed Pharmaceuticals stock forecast
InMed Pharmaceuticals financial statements
| Jun 2021 | 0 | -3.25M | |
|---|---|---|---|
| Sep 2021 | 0 | -2.97M | |
| Dec 2021 | 265.09K | -4.28M | -1615.6% |
| Mar 2022 | 309.58K | -3.50M | -1132.69% |
| Jun 2021 | 9781216 | 2.40M | 24.58% |
|---|---|---|---|
| Sep 2021 | 17327264 | 2.10M | 12.15% |
| Dec 2021 | 19383720 | 5.21M | 26.91% |
| Mar 2022 | 15485797 | 4.59M | 29.7% |
| Jun 2021 | -2.00M | -1.72K | -83.17K |
|---|---|---|---|
| Sep 2021 | -2.65M | -250K | 10.88M |
| Dec 2021 | -3.53M | 306.01K | -836.14K |
| Mar 2022 | -5.34M | -3.55K | -29.31K |
InMed Pharmaceuticals alternative data
| Aug 2023 | 12 |
|---|---|
| Sep 2023 | 12 |
| Oct 2023 | 12 |
| Nov 2023 | 12 |
| Dec 2023 | 12 |
| Jan 2024 | 12 |
| Feb 2024 | 12 |
| Mar 2024 | 12 |
| Apr 2024 | 12 |
| May 2024 | 12 |
| Jun 2024 | 12 |
| Jul 2024 | 12 |
InMed Pharmaceuticals other data
| Insider | Compensation |
|---|---|
| Mr. Eric A. Adams (1964) Pres, Chief Executive Officer & Director | $488,440 |
Mr. Bruce S. Colwill C.A., CPA, CA (1965) Chief Financial Officer & Corporation Sec. | $397,540 |
Ms. Alexandra Diane-Janet Mancini (1953) Senior Vice President of Clinical & Regulatory Affairs | $337,130 |
-
What's the price of InMed Pharmaceuticals stock today?
One share of InMed Pharmaceuticals stock can currently be purchased for approximately $4.19.
-
When is InMed Pharmaceuticals's next earnings date?
Unfortunately, InMed Pharmaceuticals's (IN.TO) next earnings date is currently unknown.
-
Does InMed Pharmaceuticals pay dividends?
No, InMed Pharmaceuticals does not pay dividends.
-
What is InMed Pharmaceuticals's stock symbol?
InMed Pharmaceuticals Inc. is traded on the TSX under the ticker symbol "IN.TO".
-
What is InMed Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of InMed Pharmaceuticals?
Shares of InMed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are InMed Pharmaceuticals's key executives?
InMed Pharmaceuticals's management team includes the following people:
- Mr. Eric A. Adams Pres, Chief Executive Officer & Director(age: 61, pay: $488,440)
- Mr. Bruce S. Colwill C.A., CPA, CA Chief Financial Officer & Corporation Sec.(age: 60, pay: $397,540)
- Ms. Alexandra Diane-Janet Mancini Senior Vice President of Clinical & Regulatory Affairs(age: 72, pay: $337,130)
-
How many employees does InMed Pharmaceuticals have?
As Jul 2024, InMed Pharmaceuticals employs 12 workers.
-
When InMed Pharmaceuticals went public?
InMed Pharmaceuticals Inc. is publicly traded company for more then 7 years since IPO on 26 Mar 2018.
-
What is InMed Pharmaceuticals's official website?
The official website for InMed Pharmaceuticals is inmedpharma.com.
-
Where are InMed Pharmaceuticals's headquarters?
InMed Pharmaceuticals is headquartered at 815 West Hastings Street, Vancouver, BC.
-
How can i contact InMed Pharmaceuticals?
InMed Pharmaceuticals's mailing address is 815 West Hastings Street, Vancouver, BC and company can be reached via phone at +60 4 669 7207.
InMed Pharmaceuticals company profile:
InMed Pharmaceuticals Inc.
inmedpharma.comTSX
12
Biotechnology
Healthcare
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Vancouver, BC V6C 1B4
:
:
:
